PEDEGO Research Unit and MRC Oulu, University of Oulu and Department of Children and Adolescents, Oulu University Hospital, Oulu, Finland.
PEDEGO Reseach Unit and MRC Oulu and Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu, Finland.
Acta Obstet Gynecol Scand. 2022 Aug;101(8):901-909. doi: 10.1111/aogs.14405. Epub 2022 Jun 15.
The use of paracetamol for pain relief in pregnancy is common. However, the influence of paracetamol on the perinatal adaptation of high-risk infants has not been studied. These data are important for safety, since another inhibitor of prostaglandin synthesis is harmful to infants born very preterm and increases serious morbidity. We studied whether the use of paracetamol had an adverse influence on neonatal adaptation and the outcomes of infants during the first hospitalization.
We studied the patient records of high-risk mothers and their infants born before 32 weeks of gestation for multiple variables over a period of 84 months in Oulu University Hospital, a regional tertiary care hospital caring for high-risk deliveries and providing neonatal intensive care. In a matched cohort setting, the exposition was defined as paracetamol use <24 h before childbirth. The controls had consumed no paracetamol up to 1 week before delivery. Infants with major anomalies were excluded. The primary outcome was defined as the need for early interventional treatments for the preterm infants. Outcomes during the first hospitalization were also studied.
Altogether, 170 fetuses from 149 mothers were exposed to paracetamol during the study period. The control population, delivering during the same period, consisted of 118 non-exposed fetuses from 104 mothers. Among them, the mothers were pairwise matched according to their medications, amniotic fluid leakage time, clinical infections, and delivery mode. After matching, 72 mothers/group remained, resulting in 88 paracetamol-exposed infants and 85 controls. No perinatal adverse reactions were detected. There were no differences in either circulatory support during the first postnatal day or in the risk for major diseases during the first hospitalization. Paracetamol-exposed infants needed fewer acute delivery room therapies (51.1% vs 65.9%, mean difference -14.89; 95% confidence interval -0.29 to -0.003). Maternal total paracetamol dose in the 1 week before delivery correlated positively with Apgar scores.
Antenatal paracetamol given within 24 h before birth had no adverse effects on extremely or very preterm infants. The long-term safety of paracetamol and the potential acute benefits for preterm infants during perinatal transition remain to be proven in larger, prospective settings.
在怀孕期间使用扑热息痛缓解疼痛很常见。然而,扑热息痛对高危婴儿围产期适应的影响尚未得到研究。这些数据对于安全性很重要,因为另一种前列腺素合成抑制剂对极早产出生的婴儿有害,并增加严重发病率。我们研究了扑热息痛的使用是否对新生儿适应和婴儿在第一次住院期间的结果有不良影响。
我们研究了在奥卢大学医院分娩的高危母亲及其妊娠 32 周前出生的婴儿的病历,该医院是一家区域三级保健医院,负责高危分娩和提供新生儿重症监护。在匹配队列设置中,暴露被定义为在分娩前 24 小时内使用扑热息痛。对照组在分娩前 1 周内没有服用扑热息痛。排除有重大畸形的婴儿。主要结局定义为早产儿需要早期介入治疗。还研究了第一次住院期间的结果。
在研究期间,共有 149 名母亲的 170 名胎儿暴露于扑热息痛。同期分娩的对照组由 104 名母亲的 118 名未暴露胎儿组成。其中,根据母亲的用药、羊水渗漏时间、临床感染和分娩方式对母亲进行了配对匹配。匹配后,每组有 72 名母亲,结果有 88 名扑热息痛暴露婴儿和 85 名对照婴儿。未发现围产期不良反应。在出生后第一天的循环支持或第一次住院期间的主要疾病风险方面没有差异。扑热息痛暴露婴儿需要的急性产房治疗较少(51.1%对 65.9%,平均差异-14.89;95%置信区间-0.29 至-0.003)。分娩前 1 周内母亲扑热息痛的总剂量与阿普加评分呈正相关。
在分娩前 24 小时内给予产前扑热息痛对极早产儿或非常早产儿没有不良影响。在更大的前瞻性研究中,需要证明产前扑热息痛的长期安全性和对围产期过渡中早产儿的潜在急性益处。